Featured

Spain just surpassed Italy to become the world’s healthiest country.

There are ~1,400 new molecular entities (NMEs) in clinical trials across ~3,200 indications.

Top-10 Drug Industry Ranking by Sales and Product

FDA Approved Biosimilars, March 2019

An assessment of where the drug industry is focusing its R&D efforts.

Pharmaceutical groups are spending heavily to influence public opinion and policy as rising drug prices become an increasingly mainstream political talking point. 

A view of pricing in the American drug ecosystem.

FDA Approved Biosimilars, Jan 2019

The Top-50 biopharmaceutical investors in the world.

The Top-20 most expensive retail-pharmacy drugs in America range from about $300,000 per year to more than $600,000 per year.

Considering the size, resources, and global reach of the industry, pharma companies have a critical role to play in improving access to medicines that can greatly alleviate pain and suffering around the world.

The best drug launches of all time.

Magnitude of clinical benefit of cancer drugs and time to health technology assessment (HTA) decisions in Europe.

What is international pricing referencing?

The difference between what drugmakers charge and what they receive is hampering the American drug ecosystem. This divergence stems from the convoluted route a drug takes from a company to a patient.